Table 3 Studies reporting on CAF-related predictive/prognostic markers in clinical radio(chemo) therapy
From: Cancer-associated fibroblasts in radiotherapy: Bystanders or protagonists?
Ref. | Tumor type | Fibroblast marker | Experimental model | Clinical relevance |
|---|---|---|---|---|
Zhang [95] | Prostate cancer | Gene signature | Transcriptomics | Radioresistant CAF signature predict worse outcomes |
Kim [96] | Cervical cancer | Gene signatures | Transcriptomics | CAF gene-signature associated with poor prognosis & worse outcomes |
Strell [97] | Breast Cancer (DCIS) | PDGFR-β | TMA IHC | PDGFR-β stroma expression is predictive of bad RT outcomes |
Verset [98] | Colo-rectal cancer | α-SMA Ki-67 | IHC pre-& post-op | Enhanced α-SMA/epithelial ratio after RT. ↑ α-SMA /epithelial ratios correlate with bad clinical outcomes |
Matsuoka [99] | Oral squamous cell carcinoma (OSCC) | α-SMA CD163 | IHC whole specimens | High abundance of CAFs & TAMs correlates with poor prognosis and bad response to neoadjuvant CRT |
Saigusa, [100] | Rectal cancer | FAPα SDF-1 | Gene expression pre-op samples | Enhanced expression of FAPα and SDF-1 correlates with poor prognosis |